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The essential oil produced from the seed of Anethum graveolens L. (Umbelliferae) was tested in vitro and in vivo anti-Candida
activity. The microbroth dilution method was used in the minimal inhibitory concentration (MIC), according to M27-A3 of
the guidelines of the Clinical and Laboratory Standard Institute (CLSI). And then, eﬃcacy evaluation of essential oil in the
prophylaxis and treatment of experimental vaginal candidiasis was performed in immunosuppressed mice. The anti-Candida
activity was analyzed by microbiological and histological techniques and was compared with that of ﬂuconazole (FCZ). The
results showed essential oil was active in vitro against all tested strains, with MICs ranging from 0.312µL/mL (for C. tropicalis,
C. parapsilosis, and C. krusei) to 0.625µL/mL (for 6 isolated C. albicans strains). Essential oil (2% v/v) was highly eﬃcacious in
accelerating C. albicans 09-1555 clearance from experimentally infected mice vagina by prophylaxis and therapeutic treatments. In
boththerapeuticeﬃcacyandprophylaxisstudies,thehistologicalﬁndingsconﬁrmedthemicrobiologicalresults.Theexperimental
results revealed that the tested essential oil is eﬀective against vulvovaginal candidiasis in immunosuppressed mice.
1.Introduction
Candida albicans is the most common cause of opportunistic
fungal disease in humans. In recent years, the nonalbicans
Candida spp., such as Candida tropicalis, Candida glabrata,
Candida parapsilosis, and Candida krusei, have also emerged
as signiﬁcant pathogens [1, 2]. Vulvovaginal candidosis
(VVC) is one of the most common clinical manifestations
of Candida spp., aﬀecting 70–75% of women at least once in
theirlifetime[3].Thereareseveralfactorsthatcanleadtothe
developmentofcandidosis;theseincludeimmunodeﬁciency,
endocrine disorders, and malignant diseases. Majority of the
clinically used antifungals suﬀer from various drawbacks
in terms of toxicity, drug-drug interactions, and lack of
fungicidal eﬃcacy, high cost, and emergence of resistant
strains resulting from frequent usage [4, 5]. For example,
amphotericin B is very toxic, while others, such as FCZ, are
limited because of the high rate of primary and secondary
resistance [6]. Despite the recent introduction of new
antifungal drugs, these are still limited in number; hence,
the great demand for novel antifungal agents justiﬁes the
intense search for new drugs that are more eﬀective and less
toxic than those already in use [7]. The essential oils from
many plants are known to possess antiviral, insecticidal, and
antioxidant properties as well as antibacterial and antifungal
activities [8, 9].
A. graveolens, one of species of Umbelliferae, is a
traditional Chinese herb. The essential oil obtained by
steam distillation from their seeds were used early in the
last century to treat many pathological conditions, such
as disease of the uterus, cervical ectropion [10]. Some
researchers have reported that essential oil from the seed of
A. graveolens, a material not native to Xingjiang (China),
possessed anti-C. albicans activity [11, 12]. However, to the
best of our knowledge, the anti-Candida activity of essential
oil from the seed of A. graveolens has not been demonstrated
both in vitro and in vivo. Thus, the objective of the current
research is to evaluate its anti-Candida activity in vitro and2 Evidence-Based Complementary and Alternative Medicine
in vivo in order to develop new antifungal agents from
natural products.
2.MaterialsandMethods
2.1. Plant Materials. The seed of A. graveolens were procured
from the Xinjiang Uighur Medical College, located in Hotan,
Xinjiang, China.
2.2. Essential Oil Isolation. The essential oil was obtained by
steam distillation. The oil was dried over anhydrous Na2SO4
and preserved in a sealed vial at 4◦C until further use. The
yield of essential oil from the seed of A. graveolens was 3.5%.
2.3. Animals. Female BALB/c mice (22 ± 2g) were obtained
from the Laboratory Animal Center of Wuhan University
(Wuhan, China). The photoperiods were adjusted daily to
a cycle of 12h of light and 12h of darkness. The environ-
mental temperature and relative humidity was constantly
maintained at 21 ± 2◦C and 50–70%, respectively. The mice
were fed ad libitum on a diet of standard pellets and water.
The study received clearance from the Institutional Animal
EthicalCommittee(IAEC)oftheCommitteeforthePurpose
of Control and Supervision of Experiments on Animals
(CPCSEA), Wuhan University, Wuhan, China.
2.4. Microorganisms. The 10 isolates of Candida studied in
this work include C. albicans (n = 6), C. tropicalis (n = 1),
C. parapsilosis (n = 1), and C. krusei (n = 1). All Candida
species were clinically isolated from infected patients in the
Department of Dermatology and Venereology of the Union
Hospital located in Wuhan, China. The isolated positions of
Candida species are presented in Table 1. All clinical isolates
were identiﬁed according to morphology on corn meal agar,
followed by germ tube formation, thick-walled spores, yeast
spores, and assimilation-fermentation proﬁles in the API
20 system (bioM´ erieux, Marcy l’´ Etoile, France). For the in
vitro experiment, all isolated strains were tested and yeast
colonies were adjusted density of 1 × 103 CFU/mL with
haemocytometer. For the in vivo experiment, the C. albicans
09-1555 was used. It was isolated from vagina and adjusted
density of 6 × 106 CFU/mL with haemocytometer.
2.5. In Vitro Susceptibility Tests. The broth macrodilution
protocols based on the CLSI reference document M27-A3
[13] with modiﬁcations was used to determine minimal
inhibitory concentration (MIC) for yeasts.
Tests were performed in sterile 96-well plates, into which
100µL of RPMI-1640 (without sodium bicarbonate and
L-glutamine at pH 7.0) were added to each well. Before
inoculum, 100µL of the essential oil was added to the ﬁrst
well and serially diluted from the ﬁrst well by taking 100µL
into the second. This twofold dilution was continued down
the plate, after which 100µL from the 10th column of the
plate was discarded. The 11th column of the plate was
reserved for negative control wells (without inoculation),
and the last column was reserved for the positive growth
control wells (without essential oil or FCZ). The essential
oil and FCZ concentrations ranged from 20–0.039µL/mL
Table 1: Isolated positions of the Candida species.
Strain Number Isolating position
C. albican 09-1519 Coronary sulcus
C. albican 09-1522 Throat swab
C. albican 09-1502 Oral mucosa
C. albican 09-1634 Dejecta
C. albican 09-1555 Vagina
C. albican 09-1394 Coronary sulcus
C. krusei 09-1681 Vagina
C. tropicalis 032 Throat swab
C. parapsilosis 07-305 Hand
and 100–0.18µg/mL, respectively. Then, the yeast colonies
were suspended in RPMI 1640 medium and adjusted 1 ×
103 CFU/mLwithhaemocytometer(twicetheﬁnalinoculum
size), 100µL was added to each well of the 96-well plates.
The tests 96-well plates were incubated at 37◦Cf o r4 8h
(Candida spp.), after which the MICs were determined.
MICs were deﬁned as the lowest concentration of the test
substances that prevented visible growth of microorganisms.
All experiments were performed in triplicate.
2.6. In Vivo Activity of Essential Oil against Candida albicans
09-1555. The mice were maintained under pseudoestrus by
giving them estradiol benzoate. These were then immuno-
suppressed by giving them dexamethasone, as previously
reported by Martinez et al. [14]. In brief, the mice received
estradiol benzoate on day 6 before inoculation (0.1mg/20g,
onceeverytwodays,s.c.).Theythenreceiveddexamethasone
on day 1 before inoculation and on day 3 after inoculation
(22.5µg/20g, once a day, i.p.). On inoculation day, the
mice were inoculated intravaginally with 6 × 106 cells of C.
albicans 09-1555 in 20µL.
2.7. Prophylactic Treatment. Prior to the infection of the
animals, they were separated randomly into 10 prophylactic
groups (Groups P). Control (CK) (n = 10) was the
negative control group that had neither infected nor treated
animals. Group 1 (n = 10) had infected, untreated but
not immunosuppressed animals; this group served to study
the impact of immunosuppression on the development
of the infection. Group 2 (n = 10) was the positive
control group that had mice that were immunosuppressed
and inoculated intravaginally with C. albicans 09-1555; this
group received 20µL of excipient solution [1% sodium
carboxymethylcellulose (CMC-Na), including 0.01% Tween
20] twice a day. Group P1 (n = 10) consisted of treated
groups that had immunosuppressed and infected animals
that received FCZ (20µL at 100µg/mL). Groups P2, P3, and
P4 (n = 10 in each group) were the treated groups that
had immunosuppressed and infected animals that received
essential oils (20µL at 2, 1, and 0.0625% v/v). This treatment
began 2 days before the inoculation of C. albicans 09-1555 in
thevaginaandcontinued15daysthereafteratadoseof20µL
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2.8. Therapeutic Treatment. Prior to inoculation, animals
(n = 10) were separated randomly into 4 groups: Groups
T1, T2, T3, and T4 (n = 10 in each group), all of which
received therapeutic treatment with FCZ (100µg/mL) and
essential oils (20µL at 2, 1, and 0.0625% v/v), respectively;
all groups also received the same concentrations as the
prophylaxis.Thistreatmentbegan4dayaftertheinoculation
and continued for 15 days thereafter at a dose of 20µLt w i c e
a day by intravaginal route. These CK, Group 1 and Group
2 served as controls for both prophylactic and therapeutic
treatments.
2.9.TheMicrobiologicalTest. Fortheprophylactictreatment,
the evaluation of vaginal burden was performed on samples
washed with 1mL of sterile saline buﬀer. The obtained cells
were harvested by centrifugation at 3200×g for 15min. This
operation was repeated on days 2, 4, 8, 10, 12, and 15 after
inoculation to observe the course of infection. Determina-
tion of the number of Candida organisms was conducted in
duplicate after performing serial 10-fold dilution of washing
ﬂuid and plating on Sabouraud glucose agar containing
0.05% of chloramphenicol. All plates were incubated at 37◦C
for 24h for each series of dilutions. For the therapeutic
treatments, the evaluation of vaginal burden was carried out
on days 4, 8, 10, 12, and 15 after-infection to observe the
course of infection.
2.10. The Histological Data. Vaginas were removed and
longitudinally opened. These were then ﬁxed in 10%
formaldehyde solution for at least 48h, stained using the
periodic acid-Schiﬀ (PAS) stain for fungal visualization. For
the prophylactic treatment, the vaginas were removed on
days 2, 8, and 15 after inoculation to observe the course of
infection. For the therapeutic treatments, the vaginas were
removed on days 4, 8, and 15 after-infection to observe the
course of infection.
2.11. Statistical Analysis. All experiments were done in
triplicate, and the results were reported as mean ± S.E.M.
(n = 6). The data were analyzed by one-way ANOVA.
Statistically signiﬁcant eﬀects were further analyzed, and
means were compared using Duncan’s multiple range test.
Statistical signiﬁcance was determined at P<. 01.
3. Results
3.1. Antifungal Susceptibility Test. In vitro antifungal activity
of essential oil was investigated against 10 clinical strains of
yeasts. The MICs value is reported in Table 2. The results
showed that the essential oil was active against all the tested
strains. For C. tropicalis, C. parapsilosis, and C. krusei strains,
MIC (0.312µL/mL) values were similar. For the 6 isolated
C. albicans strains, MIC (0.625µL/mL) values were also the
same.
3.2. Microbiological Results of Prophylactic and Therapeutic
Treatment. After establishing activity in vitro,l o wv a l u e s
of MICs were obtained, and we examined the activity of
essential oil in vivo. The experimental model of the vaginal
Table 2: Antifungal activities of essential oil from the seed of A.
graveolens against Candida spp.
Strain Fluconazole
(µg/mL) MIC
Essential oil
(µL/mL) MIC
C. albicans 09-1519 3.125 0.625
C. albicans 09-1522 3.125 0.625
C. albicans 09-1502 1.56 0.625
C. albicans 09-1634 1.56 0.625
C. albicans 09-1555 3.125 0.625
C. albicans 09-1394 3.125 0.625
C. krusei 09-1681 25 0.312
C. parapsilosis 07-305 0.78 0.312
C. tropicals 032 3.125 0.312
candidiasis model was used, and the anti-Candida activity of
essential oil in vivo was evaluated.
In the prophylactic treatment (Figure 1), prior to the
initiation of the experiments, individual vaginal cavity
cultures were performed and no Candida organisms were
found. Essential oil and FCZ exerted a marked acceleration
oftheclearanceoftheyeast,asdemonstratedbyastatistically
signiﬁcant decrease in cfu counts 15 days after the vaginal
challenge, compared with control Group 2. The clearance
values with diﬀerent essential oil concentrations suggest a
substantialessentialoildosedependenceoffungusclearance.
As with all dose regimens, the infection was decreased in 15
days, whereas the untreated control mice remained infected
(approximately log 5.16 ± 2.36 C. albicans cfu/mL of the
vaginal ﬂuid). In comparative terms, the acceleration of
Candida clearance in mice treated with FCZ (100µg/mL)
solution substantially overlapped the activity of a 1% v/v
solution of essential oil. On the other hand, no eﬀect on the
rate of fungal clearance was observed in mice treated with
essential oil-untreated animals, given the 1% CMC solution,
including 0.01% Tween 20. The mice in CK (negative control
group: neither infected nor treated animals) showed negative
culture results throughout the experiment. Essential oil
showed stronger anti-Candida activity than FCZ, similar to
the results obtained in vitro.
In the therapeutic treatment (Figure 2), just before the
inoculation with Candida cells, the vaginal cavities of all the
mice were sampled and shown to be free from infection. In
order to verify the establishment of the infection 4 days after
inoculation, all the groups of animals were re-sampled. The
results showed that the vaginal swabs were positive for all
groups of animals.
After 15 consecutive days of therapeutic treatment (day
15), the viable C. albicans 09-1555 cells for FCZ (100µg/mL)
and essential oils (2, 1, and 0.0625% v/v) treatments showed
values of log 3.6 ± 1.77 and log 2.24 ± 1.93, 3.43 ± 1.25
and 4.19 ± 3cfu/mL, respectively, indicating a signiﬁcant
reduction of Candida organisms compared with Group 2
with a value of 5.16 ± 2.36cfu/mL (P<. 01). However, there
was no signiﬁcant diﬀerence between FCZ (100µg/mL) and
essentialoil1%(P>. 05).CKshowednegativecultureresults
throughout the experiment. The infected animals in Group 14 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Microbiological study of the prophylactic eﬃcacy of essential oil versus FCZ against vaginal candidiasis in mice. Outcome
of vaginal infection by C. albicans 09-1555 in immunosuppressed BALB/c mice inoculated intravaginally with essential oil and FCZ.
CK: negative control group (no Candida was found in the vaginal lumina). Group 1: infected, untreated but not immunosuppressed
animals. Group 2: positive control group, immunosuppressed inoculated intravaginally with C. albicans 09-1555, received excipient. Group
P1: treated groups: immunosuppressed, infected animals that received FCZ (20µL at 100µg/mL). Groups P2, P3, P4: treated groups:
immunosuppressed, infected animals that received essential oils (20µL at 2, 1, and 0.0625% v/v). The value log cfu was showed by the
mean ± S.E.M. (n = 6). ∗∗: compared with Group 2 (P<. 01); ∗: compared with Group 2 (P<. 05).
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗∗
∗∗
∗∗
∗∗
0
1
2
3
4
5
6
l
o
g
c
f
u
/
m
L
Group 1
(day)
Group 2
Group T1
Group T2
Group T3
Group T4
4 8 10 12 15
Figure 2:MicrobiologicalstudyofthetherapeuticeﬃcacyofessentialoilversusFCZagainstvaginalcandidiasisinmice.Outcomeofvaginal
infection by C. albicans 09-1555 in immunosuppressed BALB/c mice inoculated intravaginally with essential oil and FCZ. CK: negative
control group (no Candida was found in the vaginal lumina). Group 1: infected, untreated but not immunosuppressed animals. Group 2:
positivecontrolgroup,immunosuppressed,inoculatedintravaginallywithC.albicans09-1555,receivedexcipient.GroupT1:treatedgroups:
immunosuppressed, infected animals that received FCZ (20µL at 100µg/mL). Groups T2, T3, T4: treated groups: immunosuppressed,
infected animals that received essential oils (20µL at 2, 1, and 0.0625% v/v). The value log cfu was showed by the mean ± S.E.M. (n = 6).
∗∗: compared with Group 2 (P<. 01); ∗: compared with Group 2 (P<. 05).Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: Microscopic observation of the prophylactic eﬃcacy of essential oil versus FCZ against vaginal candidiasis in BALB/c mice on
days 2, 8, and 15 after-infection (periodic acid-Schiﬀ staining, 400x). CK: neither infected nor treated animals. Group 1: infected, untreated
but not immunosuppressed animals. Group 2: immunosuppressed and inoculated intravaginally with C. albicans 09-1555, and animals that
received excipient. Group P1: treated groups: immunosuppressed, infected animals that received FCZ (20µL at 100µg/mL). Groups P2, P3,
P4: treated groups: immunosuppressed, infected animals that received essential oils (20µL at 2, 1, and 0.0625% v/v).The bar is 10µm.
(nonimmunosuppressed infected and untreated group) had
no Candida cell.
3.3. Histological Test. Prophylactic treatment: in all animals,
thepresenceofyeastwasfoundonsectionsofvaginasstained
withPAS.Ininfecteduntreatedmice,bothbuddingyeastand
the pseudohyphae form of C. albicans 09-1555—dark with
PAS stain—were found in the luminal vagina. At the surface
of the epithelium, we also noticed keratin debris, whereas in
the noninfected control group, no Candida was observed in
the luminal vagina.
The infected mice from Groups P1–P4 (immunosup-
pressed and then infected and treated with FCZ and essential
oil) all showed budding yeast and pseudohyphae in the
vaginal luminal, on day 2 after inoculation (Figure 3).
However, those from Group 2 (immunosuppressed infected
and treated with excipient) showed large amounts of yeast
and pseudohyphae in the vaginal luminal (Figure 3). Other
groups showed yeast and pseudohyphae in the vaginal
luminal dose dependently. Samples from Groups P1, P2, P3,
a n dP 4r e c e i v e dF C Z( 1 0 0 µg/mL) and essential oils (2, 1,
0.0625% v/v) on day 8 after inoculation, less than that for
Candida in the vaginal luminal (Figure 3), compared with
Group2(Figure 3).Onthe15thdayafterinoculation,Group
P2 showed no Candida organisms detected by histological
techniques (Figure 3) and it showed the same aspect as CK
(neither infected nor treated animals), which was better than
G r o u pP 1( i n f e c t e dg r o u p st r e a t e dw i t hF C Z ) .
In Group 1 (nonimmunosuppressed infected and un-
treated group), the infected animals had few pseudohyphae
in the vaginal lumen on day 2 after inoculation, and no
Candida was observed in the vaginal lumina on day 15.
Therapeutictreatment:vaginalsections of alltheanimals
werealsostudiedbylightmicroscopy.Infectedanduntreated
mice demonstrated the presence of C. albicans 09-1555 at the
surface of the epithelium with desquamation of superﬁcial
layers, whereas in CK (neither infected nor treated animals),
no Candida was found in the vaginal lumina (Figure 4).
Onday4afterinoculation,theinfectedanimalshadgreat
amounts of budding yeast and pseudohyphae in the vaginal
lumina (Groups T1–T4 and Group 2) (Figure 4).
On day 8 after administration, therapeutic treatment
with FCZ and essential oils (Groups T1–T4) signiﬁ-
cantly reduced the fungal burden compared with Group 2
(immunosuppressed infected and treated with excipient) in
the vaginal luminal (Figure 4).
On the 15th day after administration, Group T2,
(immunosuppressed infected and treated with essential
oil 2% v/v) completely eradicated the vaginal Can-
dida (Figure 4). Regarding Group T1 (immunosuppressed
infected and treated with FCZ) (Figure 4), only a few
Candida was found in the vaginal lumina similar to Group
T3 (immunosuppressed infected and treated with essential
oil 1% v/v).Vaginal sections in CK and Group1 presented the
sameaspectthatnoCandidawasfoundinthevaginallumina
(Figure 4).
4. Discussions
A. graveolens is found in many places, such as India, Europe,
United States, Turkey, and China. It has been used for
cooking and in Uygur medicine since ancient times in
China. Aromatic herbal oils used for cooking and ﬂavoring
cover a broad spectrum of antimicrobial activities. The main6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Microscopic observation of therapeutic eﬃcacy of essential oil versus FCZ against vaginal candidiasis in BALB/c mice on Post-
infection day 4, day 8, day 15 (periodic acid-Schiﬀ staining, 400x). CK: neither infected nor treated animals. Group 1: infected, untreated
but not immunosuppressed animals. Group 2: immunosuppressed, inoculated intravaginally with C. albicans 09-1555, received excipient.
Group T1: treated groups:immunosuppressed, infected animals received FCZ (20µL at 100µg/mL). Groups T2, T3, T4 treated groups:
immunosuppressed, infected animals received essential oils (20µL at 2% v/v, 1% v/v, 0.0625% v/v). The bar is 10µm.
chemical components of essential oil from the seed of A.
graveolens are carvone and limonene [10]. These ﬁndings
are similar to those reported in other studies [15, 16].
These activities may be attributed to the presence of the
aforementioned main chemical components. Meanwhile,
other authors have reported that carvone and limonene have
antimicrobial activities [17].
In this paper, we have conﬁrmed and extended existing
data on in vitro activity of essential oil against an elevated
number of clinical isolates of C. albicans and other Candida
species. The MIC values ranged from 1.56–3.15µg/mL for
FCZ against C. albicans strains. The C. albicans 09-1555
strain was nonsusceptible to FCZ. The MIC value was
3.15µg/mL. Another paper has reported that an FCZ MIC
of ≥2µg/mL is considered nonsusceptible; it also reported
av a l u eo f≤2µg/mL as the FCZ susceptibility [18]. Yili et
al. [11] have shown that the MIC value of essential oil from
the seed of A. graveolens against C. albicans was 2.73µg/mL
by broth dilution method. Although these results seem to
contradict ours, we think this diﬀerence may depend on
experimental conditions and material origin.
As far as the vaginal candidiasis model is concerned,
the presence of estrogen is a very important factor for the
persistence of experimental Candidal vaginitis [19, 20]. Our
results showed that the control group of immunosuppressed,
infected, and untreated animals remained infected through-
out the experiment. In contrast, 15 days after inoculation,
thegroupofnonimmunosuppressed,infected,anduntreated
mice showed spontaneous clearing of the yeast. These data
conﬁrmed that immunosuppression is necessary to the suc-
cess of this model [14]. In this model, the antifungal activity
of essential oil, which is being compared with that of FCZ,
has been investigated and determined by microbiological
tests and histological study. To the best of our knowledge,
this is the ﬁrst report showing the eﬀect of essential oil from
the seed of A. graveolens treatment on vaginal candidiasis.
To allow optimal adhesion of essential oil and FCZ on the
mucosal vagina, a gelatinous suspension of 1% CMC-Na was
usedasexcipienttotreatmicethroughtheintravaginalroute.
Both 1% CMC-Na and 0.8% agar were used as excipients
[20, 21]. On the basis of preliminary tests, 32-fold MIC of
FCZ (µg/mL) was chosen as a reference treatment; likewise,
2-fold MIC (0.0652% v/v), 32-fold MIC (1% v/v), and 64-
fold MIC of essential oil (2% v/v) were chosen as reference
treatments.
Some authors have already demonstrated the eﬃcacy
of azoles in vaginal candidiasis prophylaxis [22], while
others have also demonstrated the eﬃcacy of carvacrol and
eugenol [20]. In this work, we investigated the eﬃcacy of
essential oil from the seed of A. graveolens by prophylactic
treatment. For the in vivo results, 15 days after treatment,
The mice treated with essential oils (2, 1, 0.0625% v/v)
remained infected, with average Candida counts recorded as
log 1.81 ± 1.4, 3.1 ± 1.23, 4.01 ± 2.73cfu/mL, respectively.
But they were signiﬁcantly lower than those found in the
infected untreated control group. Group 2 showed positive
Candida cultures throughout the experiment. In Group P2
(the animals treated with essential oil 2% v/v), few animals
showed negative culture on 15 days after the interruption
of the treatment. The histological examination agreed with
the microbiological results. Prophylactic treatments with
FCZ, essential oil (1% v/v), and essential oil (0.0625% v/v)Evidence-Based Complementary and Alternative Medicine 7
only seemed to be less eﬀective than that with essential oil
(2% v/v).
Furthermore, vaginal burden in the remaining infected
animals was signiﬁcantly less than in the control group, and
fewC.albicans09-1555weredetectedonthevaginalsections.
From these results, essential oil (2% v/v) was shown to be the
most eﬀective in preventing Candida vaginal infection.
Therapeutic treatment with essential oil (2% v/v) for
15 days led to signiﬁcant clearance of yeast from the
majority of animals exhibiting negative Candida culture
compared with Group 2 (the infected untreated); however,
few Candida cells were detected in one remaining infected
mice by microbiological results, with no detectable Candida
cells using histological examination. Concerning the animals
treated with essential oil (1% v/v), essential oil (0.0625%
v/v), few Candida cells were in the vaginal lumina detected
by both microbiological and histological examinations. The
results showed similar values for animals treated with FCZ
was (100µg/mL) and with essential oil (1% v/v). The FCZ
also used as positive control by other author. Although
these results seem to contradict those of previous works,
the diﬀerence may depend on experimental conditions, such
as administration time, inoculum size, and diﬀerent animal
strains [23, 24]. Therefore, the therapeutic treatment with
essential oil (2% v/v) was shown as the most eﬀective in
preventing Candida vaginal infection.
The results of our investigations demonstrate that essen-
tial oil treatment is eﬃcacious in resolving experimen-
tal Candida infection. In the case of the nonsusceptible
organism, treatment with essential oil was comparable to a
standard treatment with FCZ.
5. Conclusion
Based on these results, it can be concluded that essential oil
fromtheseedof A.graveolenspossessesanti-Candidaactivity
in vitro and in vivo. These results support the traditional use
of essential oil from the seed of A. graveolens in antimicrobial
capabilities, and it could be considered as a kind of new
parts for medicinal material which is useful and potential in
prevention and treatment of monilial vaginitis.
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